Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amylyx PharmaceuticalsAMLX +0.34%33 EV-to-EBITDA is -10.62 as of Jul. 24, 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 742 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks worse than 134770.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Amylyx Pharmaceuticals's enterprise value is $1,687.19 Mil.
Amylyx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-158.80 Mil. Therefore, Amylyx Pharmaceuticals's EV-to-EBITDA for today is -10.62.
The historical rank and industry rank for Amylyx Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
AMLX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -138.42 Med: -5.92 Max: 23.41
Current: -10.62
During the past 7 years, the highest EV-to-EBITDA of Amylyx Pharmaceuticals was 23.41. The lowest was -138.42. And the median was -5.92.
AMLX's EV-to-EBITDA is ranked worse than 100% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs AMLX: -10.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amylyx Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Amylyx Pharmaceuticals's share price for today is $17.64.
Amylyx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's EV-to-EBITDA falls into.
Amylyx Pharmaceuticals's current Enterprise Value is $1,687.19 Mil.
Amylyx Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-158.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (AMLX) has a EV-to-EBITDA of -10.62 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Amylyx Pharmaceuticals. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #999999 out of 742 companies in the Drug Manufacturers industry.
Is Amylyx Pharmaceuticals' EV-to-EBITDA too high?
Amylyx Pharmaceuticals' current EV-to-EBITDA is -10.62. Based on the distribution chart, Amylyx Pharmaceuticals ranks #999999 out of 742 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' EV-to-EBITDA compare to ANIP and TRLV?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #999999 out of 742 companies for EV-to-EBITDA. This places Amylyx Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Amylyx Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current EV-to-EBITDA is -10.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current EV-to-EBITDA of -10.62. The current EV-to-EBITDA is -10.62. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current EV-to-EBITDA is -10.62 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
